VOLUME 1 (2010)
View Archive »
About The Cover
J124 and J128 have anti-metastatic efficacy in a metastasis model. (a), Livers of mice treated with J124 and J128 as opposed to vehicle alone show distinctive difference in the number of tumor nodules. (b), Representative liver H&E sections of treated and untreated animals underscore differential liver metastasis load. See Schmidt-Kittler et al. (pp. 339-348) and commentary on p. 315-316 of this issue for details.
|
|
Table of Contents
|
| P3Kα: A Driver of Tumor Metastasis |
|
https://doi.org/10.18632/oncotarget.162
|
| 315-316 |
|
| The heme oxygenase1 and cFLIP in acute myeloid leukemias: two nonredundant but mutually exclusive cellular safeguards protecting cells against TNFinduced cell death |
|
https://doi.org/10.18632/oncotarget.163
|
| 317-319 |
Reviews
|
| Membrane lipids in invadopodia and podosomes: Key structures for cancer invasion and metastasis |
|
https://doi.org/10.18632/oncotarget.164
|
| 320-328 |
Research Papers
|
| CD277 is a negative costimulatory molecule universally expressed by ovarian cancer microenvironmental cells |
|
https://doi.org/10.18632/oncotarget.165
|
| 329-338 |
|
| PI3Kα Inhibitors That Inhibit Metastasis |
|
https://doi.org/10.18632/oncotarget.166
|
| 339-348 |
|
| miR449a causes Rbdependent cell cycle arrest and senescence in prostate cancer cells |
|
https://doi.org/10.18632/oncotarget.167
|
| 349-358 |
|
| FLIP regulation of HO1 and TNF signalling in human acute myeloid leukemia provides a unique secondary antiapoptotic mechanism |
|
https://doi.org/10.18632/oncotarget.168
|
| 359-366 |
Research Perspectives
|
| What are genomewide association studies telling us about Bcell tumor development |
|
https://doi.org/10.18632/oncotarget.169
|
| 367-372 |
|
| Mouse models of hepatocarcinogenesis: What can we learn for the prevention of human hepatocellular carcinoma |
|
https://doi.org/10.18632/oncotarget.170
|
| 373-378 |
|
| The Siah2HIFFoxA2 axis in prostate cancer – new markers and therapeutic opportunities |
|
https://doi.org/10.18632/oncotarget.171
|
| 379-385 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC